Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer

Oncotype DX (ODX), a 21-gene assay, predicts the recurrence risk in early breast cancer; however, it has high costs and long testing times. We aimed to identify clinicopathological factors that can predict the ODX risk group and serve as alternatives to the ODX test. This retrospective study include...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-09, Vol.15 (18), p.4451
Main Authors: Song, Ran, Lee, Dong-Eun, Lee, Eun-Gyeong, Lee, Seeyoun, Kang, Han-Sung, Han, Jai Hong, Lee, Keun Seok, Sim, Sung Hoon, Chae, Heejung, Kwon, Youngmee, Woo, Jaeyeon, Jung, So-Youn
Format: Article
Language:English
Subjects:
Age
Body mass index
Breast cancer
Cancer
Cancer patients
Cancer therapies
Care and treatment
Chemotherapy
Decision making
Diagnosis
Endocrine therapy
Epidermal growth factor
ErbB-2 protein
Estrogen
Estrogen receptors
Health aspects
Lymph nodes
Oncology, Experimental
p53 Protein
Patients
Progesterone
Radiation therapy
Regression analysis
Risk groups
Surgery
Tumor proteins
Tumors
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oncotype DX (ODX), a 21-gene assay, predicts the recurrence risk in early breast cancer; however, it has high costs and long testing times. We aimed to identify clinicopathological factors that can predict the ODX risk group and serve as alternatives to the ODX test. This retrospective study included 547 estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and lymph node-negative breast cancer patients who underwent ODX testing. Based on the recurrence scores, three ODX risk categories (low: 0–15, intermediate: 16–25, and high: 26–100) were established in patients aged ≤50 years (n = 379), whereas two ODX risk categories (low: 0–25 and high: 26–100) were established in patients aged >50 years (n = 168). Factors selected for analysis included body mass index, menopausal status, type of surgery, and pathological and immunohistochemical features. The ODX risk groups showed significant association with histologic grade (p = 0.0002), progesterone receptor expression (p < 0.0001), Ki-67 (p < 0.0001), and p53 expression (p = 0.023) in patients aged ≤50 years. In patients aged >50 years, tumor size (p = 0.022), Ki-67 (p = 0.001), and p53 expression (p = 0.001) were significantly associated with the risk group. Certain clinicopathological factors can predict the ODX risk group and enable decision-making on adjuvant chemotherapy; these factors differ according to age.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15184451